Jana Graf1, Rudolf A Jörres, Tanja Lucke, Dennis Nowak, Claus F Vogelmeier, Joachim H Ficker. 1. Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich, German Center for Lung Research (DZL), Munich, Germany; Department of Medicine, Pulmonary, Critical Care and Sleep Medicine, University Hospitals of Gießen and Marburg, Marburg site, German Center for Lung Research (DZL); Department of Respiratory Medicine, Allergology and Sleep Medicine, General Hospital Nürnberg, Paracelsus Medical University, Nürnberg, Germany.
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is common around the world and carries a high morbidity and mortality. Symptom- and risk-oriented drug treatment is recommended, both in Germany and in other countries. It is not yet known to what extent the treatment that is actually delivered in Germany corresponds to the current recommendations in the guidelines. METHODS: As recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in 2017, 2281 patients of the national COPD cohort COSYCONET (COPD and Systemic Consequences-Comorbidities Network) were classified into Gold classes A-D on the basis of disease-specific manifestations and the frequency of exacerbations. Moreover, the regular use of medications was documented and categorized according to active substance groups. For all groups, the documented treatment that was actually given was compared to the recommended treatment. RESULTS: 67.6% of the patients received a combination of a long-acting anticholinergic drug (LAMA) and a long-acting beta-mimetic drug (LABA), while 65.8% received inhaled corticosteroids (ICS), 11.7% theophylline, and 12.6% oral corticosteroids (OCS). Despite recommendations to the contrary, 66% of the patients in Groups A and B (low exacerbation rates) were treated with ICS; some of these patients carried an additional diagnosis of bronchial asthma. There was evidence of undertreatment mainly in groups C and D (high exacerbation rate), because many of the patients in these groups were not treated with LAMA or LAMA/LABA as recommended. CONCLUSION: The observed deviations from the recommended treatment, some of which were substantial, might lead to suboptimal treatment outcomes as well as to avoidable side effects of medication.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is common around the world and carries a high morbidity and mortality. Symptom- and risk-oriented drug treatment is recommended, both in Germany and in other countries. It is not yet known to what extent the treatment that is actually delivered in Germany corresponds to the current recommendations in the guidelines. METHODS: As recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in 2017, 2281 patients of the national COPD cohort COSYCONET (COPD and Systemic Consequences-Comorbidities Network) were classified into Gold classes A-D on the basis of disease-specific manifestations and the frequency of exacerbations. Moreover, the regular use of medications was documented and categorized according to active substance groups. For all groups, the documented treatment that was actually given was compared to the recommended treatment. RESULTS: 67.6% of the patients received a combination of a long-acting anticholinergic drug (LAMA) and a long-acting beta-mimetic drug (LABA), while 65.8% received inhaled corticosteroids (ICS), 11.7% theophylline, and 12.6% oral corticosteroids (OCS). Despite recommendations to the contrary, 66% of the patients in Groups A and B (low exacerbation rates) were treated with ICS; some of these patients carried an additional diagnosis of bronchial asthma. There was evidence of undertreatment mainly in groups C and D (high exacerbation rate), because many of the patients in these groups were not treated with LAMA or LAMA/LABA as recommended. CONCLUSION: The observed deviations from the recommended treatment, some of which were substantial, might lead to suboptimal treatment outcomes as well as to avoidable side effects of medication.
Authors: M E Wacker; R A Jörres; H Schulz; J Heinrich; S Karrasch; A Karch; A Koch; A Peters; R Leidl; C Vogelmeier; R Holle Journal: Respir Med Date: 2015-12-10 Impact factor: 3.415
Authors: Steven J Pascoe; David A Lipson; Nicholas Locantore; Helen Barnacle; Noushin Brealey; Rajat Mohindra; Mark T Dransfield; Ian Pavord; Neil Barnes Journal: Eur Respir J Date: 2016-07-13 Impact factor: 16.671
Authors: Jana Graf; Tanja Lucke; Ronald Herrera; Henrik Watz; Rolf Holle; Claus Vogelmeier; Joachim H Ficker; Rudolf A Jörres Journal: Pulm Pharmacol Ther Date: 2018-02-05 Impact factor: 3.410
Authors: Sarah Houben-Wilke; Rudolf A Jörres; Robert Bals; Frits M E Franssen; Sven Gläser; Rolf Holle; Annika Karch; Armin Koch; Helgo Magnussen; Anne Obst; Holger Schulz; Martijn A Spruit; Margarethe E Wacker; Tobias Welte; Emiel F M Wouters; Claus Vogelmeier; Henrik Watz Journal: Am J Respir Crit Care Med Date: 2017-01-15 Impact factor: 21.405
Authors: Kathrin Kahnert; Peter Alter; David Young; Tanja Lucke; Joachim Heinrich; Rudolf M Huber; Jürgen Behr; Margarethe Wacker; Frank Biertz; Henrik Watz; Robert Bals; Tobias Welte; Hubert Wirtz; Felix Herth; Jørgen Vestbo; Emiel F Wouters; Claus F Vogelmeier; Rudolf A Jörres Journal: Respir Med Date: 2017-12-05 Impact factor: 3.415
Authors: Helgo Magnussen; Bernd Disse; Roberto Rodriguez-Roisin; Anne Kirsten; Henrik Watz; Kay Tetzlaff; Lesley Towse; Helen Finnigan; Ronald Dahl; Marc Decramer; Pascal Chanez; Emiel F M Wouters; Peter M A Calverley Journal: N Engl J Med Date: 2014-09-08 Impact factor: 91.245
Authors: Dionne E Smid; Frits M E Franssen; Maria Gonik; Marc Miravitlles; Ciro Casanova; Borja G Cosio; Pilar de Lucas-Ramos; Jose M Marin; Cristina Martinez; Isabel Mir; Joan B Soriano; Juan P de Torres; Alvar Agusti; Nart B Atalay; Julia Billington; Afroditi K Boutou; Stefanie Brighenti-Zogg; Emma Chaplin; Samantha Coster; James W Dodd; Selina Dürr; Alberto Fernandez-Villar; Miriam T J Groenen; Miguel Guimarães; Karel Hejduk; Victoria Higgins; Nicholas S Hopkinson; Nobuyuki Horita; Sarah Houben-Wilke; Daisy J A Janssen; Melissa Jehn; Rudolf Joerres; Annika Karch; Julia L Kelly; Yu-Il Kim; Hiroshi Kimura; Vladimir Koblizek; Janwillem H Kocks; Samantha S C Kon; Namhee Kwon; Inês Ladeira; Sang-Do Lee; Joerg D Leuppi; Nicholas Locantore; José L Lopez-Campos; William D-C Man; Lana Maricic; Laura Mendoza; David Miedinger; Florin Mihaltan; Seigo Minami; Thys van der Molen; Trevor J Murrells; Nienke Nakken; Yu Nishijima; Ian J Norman; Barbora Novotna; Denis E O'Donnell; Yoshitaka Ogata; Eanes D Pereira; James Piercy; David Price; Chaicharn Pothirat; Natya Raghavan; Thomas Ringbaek; Dimitar Sajkov; Naseh Sigari; Sally Singh; Mark Small; Guilherme F da Silva; Rebecca J Tanner; Ioanna G Tsiligianni; Baykal Tulek; Nikolaos Tzanakis; Lowie E G W Vanfleteren; Henrik Watz; Katherine A Webb; Emiel F M Wouters; Guogang G Xie; Masanori Yoshikawa; Martijn A Spruit Journal: J Am Med Dir Assoc Date: 2017-12-01 Impact factor: 4.669
Authors: Johanna I Lutter; Rudolf A Jörres; Kathrin Kahnert; Larissa Schwarzkopf; Michael Studnicka; Stefan Karrasch; Holger Schulz; Claus F Vogelmeier; Rolf Holle Journal: BMC Pulm Med Date: 2020-05-29 Impact factor: 3.317
Authors: Norbert Königsdorfer; Rudolf A Jörres; Sandra Söhler; Tobias Welte; Jürgen Behr; Joachim H Ficker; Robert Bals; Henrik Watz; Johanna I Lutter; Tanja Lucke; Frank Biertz; Peter Alter; Claus F Vogelmeier; Kathrin Kahnert Journal: Patient Prefer Adherence Date: 2019-10-10 Impact factor: 2.711
Authors: Fernando J Martinez; Gary T Ferguson; Eric Bourne; Shaila Ballal; Patrick Darken; Magnus Aurivillius; Paul Dorinsky; Colin Reisner Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-01-28
Authors: Kathrin Kahnert; Rudolf A Jörres; Tanja Lucke; Franziska C Trudzinski; Pontus Mertsch; Christiane Bickert; Joachim H Ficker; Jürgen Behr; Robert Bals; Henrik Watz; Tobias Welte; Claus F Vogelmeier; Peter Alter Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-11-24
Authors: Carolina Fischer; Rudolf A Jörres; Peter Alter; Franziska C Trudzinski; Önder Yildirim; Robert Bals; Claus F Vogelmeier; Diego Kauffmann-Guerrero; Jürgen Behr; Henrik Watz; Rolf Holle; Kathrin Kahnert Journal: Patient Prefer Adherence Date: 2022-07-26 Impact factor: 2.314
Authors: Roland Buhl; Michael Dreher; Stephanie Korn; Christian Taube; Christian Stock; Christoph M Zehendner; Anke Kondla; Claus F Vogelmeier Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-10-22
Authors: Anders Løkke; Ole Hilberg; Peter Lange; Rikke Ibsen; Georgios Stratelis; Sofie de Fine Licht; Jesper Lykkegaard Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-03-16